Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Back to filter
Show all topics (10)
Related topics
Early immune response in mice immunized with inactivated vaccine against SARS-CoV-2
Nov 23, 2020
The development of a vaccine against COVID-19 is a hot topic for many research laboratories all over the world. Our aim...
CS-FNX Hitachi Koki, discover the state-of-art ultracentrifuges series
Nov 19, 2020
Hitachi Koki, as a world leading producer of centrifuges offers general purpose floor standing and table top...
Curiox webinar - how to retain more cells for Single Cell Sequencing and proteogenomics ?
Nov 19, 2020
Do you think that centrifuging cells at 500 x g is not going to cause issues? Moreover, sample prep involving...
Discover the new NovoCyte Penteon - when exceptional performance meets simplicity
Nov 18, 2020
The NovoCyte Penteon flow cytometer builds on its successful predecessor, the NovoCyte. You now have the flexibility to...
Cellular stress induces erythrocyte assembly and promotes microangiopathy
Dec 19, 2018
Microangiopathy with subsequent organ damage represents a major complication in several diseases. The mechanisms...
The need for ultra high field magnetic resonance imaging
Dec 17, 2018
MRI is a noninvasive imaging technology that is known for its superior soft tissue contrast and ability to provide...
NovoCyte Quanteon webinar: In-depth cell Proliferation through new advances in flow cytometry
Dec 11, 2018
Cell proliferation is one of the most fundamental biological processes in biology. Many of the traditional assays to...
Webinar: early detection of metabolic remodeling in pressure overload left ventricle Hypertrophy
Nov 28, 2018
Do you already heard the hypothesis that metabolic changes in the heart may precede and even trigger structural and...
IncuCyte neuronal activity assay
Nov 13, 2018
The generation and maturation of neuronal networks are necessary characteristics of neurogenesis, providing...
The most advanced software for preclinical imaging research
Nov 7, 2018
Modern imaging laboratories hosting PET/MR instruments profit from the fully integrated common imaging platform...
Preclinical PET imaging in studies of candidate therapeutics
Jun 22, 2017
Clinical and preclinical non-invasive PET imaging is employed in the development and validation of therapeutic agents for cancer and neurological disorders, and a range of other diseases. Reported studies have used numerous agents including FDG, FLT, FMISO and FAZA as early biomarkers of drug efficacy. Preclinical PET imaging has been proven in studies of therapeutic targeting and biodistribution, drug target interactions, pharmacodynamics and toxicology. These methods have helped facilitate the development of therapeutic agents that are now clinically available. Probably two of the most common uses of preclinical PET imaging in drug discovery are studies of compound targeting and biodistribution and therapeutic efficacy. In the article, you can find a brief introduction to preclinical PET imaging for such studies.
Brand profile
